The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women

Journal of Gynecologic Oncology

Volumn 21, Issue 2, 2010, Pages 102-105

  Lee, Seo Yeong ^a   Kim, Mi Kyoung ^a   Park, Hyun ^a   Yoon, Bo Sung ^a   Seong, Seok Ju ^a   Kang, Jin Hee ^a   Jun, Hye Sun ^a   Park, Chong Taik ^a  

^a CHA University   (South Korea)

Author keywords

Endometrial hyperplasia; Korean women; LNG IUS; Mirena; Progestin

Indexed keywords

LEVONORGESTREL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; SOUTH KOREA;

EID: 77954488529     PISSN: 20050380     EISSN: 20050399     Source Type: Journal    
DOI: 10.3802/jgo.2010.21.2.102     Document Type: Article

References (15)

1. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: a long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985; 56: 403-12.
2. Tabata T, Yamawaki T, Yabana T, Ida M, Nishimura K, Nose Y. Natural history of endometrial hyperplasia: study of 77 patients. Arch Gynecol Obstet 2001; 265: 85-8. (Pubitemid 32494271)
3. Terakawa N, Kigawa J, Taketani Y, Yoshikawa H, Yajima A, Noda K, et al. The behavior of endometrial hyperplasia: a prospective study. Endometrial Hyperplasia Study Group. J Obstet Gynaecol Res 1997; 23: 223-30.
4. Clark TJ, Neelakantan D, Gupta JK. The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol 2006; 125: 259-64.
5. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv 2004; 59: 368-78.
6. Marsden DE, Hacker NF. Optimal management of endometrial hyperplasia. Best Pract Res Clin Obstet Gynaecol 2001; 15: 393-405.
7. Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989; 160: 126-31. (Pubitemid 19055273)
8. Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont M, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007; 57: 210-3.
9. Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008; 111: 68-73.
10. Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia: a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008; 139: 169-75.
11. Vereide AB, Kaino T, Sager G, Arnes M, Orbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol 2006; 101: 214-23.
12. Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2003; 91: 526-33.
13. Lurain JR. Uterine cancer. In: Berek JS, editor. Berek & Novak's gynecology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p.1343-402.
14. Phillips V, Graham CT, Manek S, McCluggage WG. The effects of the levonorgestrel intrauterine system (Mirena coil) on endometrial morphology. J Clin Pathol 2003; 56: 305-7. (Pubitemid 36459803)
15. Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 2003; 80: 1315-24.